NovaBridge Biosciences (NBP)
NBP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.29
-2.27% on the day
Market cap
$148.8M
Micro cap
Revenue · 2023
$632K
No prior year to compare
Net income · 2023
-$207.7M
-32868.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2023.
Profile
| Field | Value |
|---|---|
| Ticker | NBP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2020 |
| SEC CIK | 0001778016 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $632K |
| Net income | -$207.7M |
| Operating income | -$72.0M |
| Net margin | -32868.5% |
| Operating margin | -11395.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $291.5M |
| Total assets | $368.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 235.5× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2025-10-30 |
| Latest annual report | 20-F | 2026-04-07 |
| Latest quarterly / interim | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 325 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $7.04 | -1.81% | $149.4M |
| NKTX | Nkarta Inc. | $2.10 | -3.23% | $150.4M |
| MENS | Jyong Biotech Ltd. | $2.04 | -2.86% | $155.1M |
| ORGO | Organogenesis Holdings Inc. | $1.21 | -1.63% | $155.7M |
| CUE | Cue Biopharma Inc. | $19.57 | -20.48% | $142.2M |
| BGM | BGM Group Ltd. | $10.48 | +2.75% | $140.0M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $1.09 | 0.00% | $138.7M |
| DERM | Journey Medical Corporation | $5.68 | -3.89% | $160.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier